

# Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/GDBB6AF65585EN.html>

Date: October 2023

Pages: 117

Price: US\$ 4,480.00 (Single User License)

ID: GDBB6AF65585EN

## Abstracts

The global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market size is expected to reach \$ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

This report studies the global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors total market, 2018-2029, (USD Million)

Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors total market, key domestic companies and share, (USD Million)

Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors revenue by player and market share 2018-2023, (USD Million)

Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors total market by Type, CAGR, 2018-2029, (USD Million)

Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Mirati Therapeutics, Novartis, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation and Jacobio Pharmaceuticals, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

### Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market, Segmentation by Type

Direct Inhibitors

Signal transduction inhibitors

### Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market, Segmentation by Application

Retail Pharmacy

Hospital Pharmacy

Online Pharmacy

### Companies Profiled:

Amgen

Mirati Therapeutics

Novartis

Genentech

Verastem Oncology

Revolution Medicines

Cardiff Oncology

Immuneering Corporation

Jacobio Pharmaceuticals

BridgeBio Pharma

Deciphera Pharmaceuticals

Elicio Therapeutics

InventisBio

Gritstone Bio

D3 Bio

## Key Questions Answered

1. How big is the global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market?
2. What is the demand of the global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market?
3. What is the year over year growth of the global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market?
4. What is the total value of the global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market?
5. Who are the major players in the global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market?

## Contents

### 1 SUPPLY SUMMARY

- 1.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
- 1.2 World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Total Market by Region (by Headquarter Location)
  - 1.3.1 World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2018-2029), (by Headquarter Location)
  - 1.3.2 United States Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2018-2029)
  - 1.3.3 China Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2018-2029)
  - 1.3.4 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2018-2029)
  - 1.3.5 Japan Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2018-2029)
  - 1.3.6 South Korea Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2018-2029)
  - 1.3.7 ASEAN Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2018-2029)
  - 1.3.8 India Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
  - 1.4.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Drivers
  - 1.4.2 Factors Affecting Demand
  - 1.4.3 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Major Market Trends

### 2 DEMAND SUMMARY

- 2.1 World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value (2018-2029)
- 2.2 World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value by Region
  - 2.2.1 World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value by Region (2018-2023)

- 2.2.2 World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value Forecast by Region (2024-2029)
- 2.3 United States Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value (2018-2029)
- 2.4 China Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value (2018-2029)
- 2.5 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value (2018-2029)
- 2.6 Japan Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value (2018-2029)
- 2.7 South Korea Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value (2018-2029)
- 2.8 ASEAN Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value (2018-2029)
- 2.9 India Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value (2018-2029)

### **3 WORLD KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG (KRAS) INHIBITORS COMPANIES COMPETITIVE ANALYSIS**

- 3.1 World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue by Player (2018-2023)
- 3.2 Industry Rank and Concentration Rate (CR)
  - 3.2.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Industry Rank of Major Players
  - 3.2.2 Global Concentration Ratios (CR4) for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors in 2022
  - 3.2.3 Global Concentration Ratios (CR8) for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors in 2022
- 3.3 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Company Evaluation Quadrant
- 3.4 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Overall Company Footprint Analysis
  - 3.4.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Region Footprint
  - 3.4.2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Company Product Type Footprint
  - 3.4.3 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Company Product Application Footprint

- 3.5 Competitive Environment
  - 3.5.1 Historical Structure of the Industry
  - 3.5.2 Barriers of Market Entry
  - 3.5.3 Factors of Competition
- 3.6 Mergers, Acquisitions Activity

## **4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)**

- 4.1 United States VS China: Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Comparison (by Headquarter Location)
  - 4.1.1 United States VS China: Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
  - 4.1.2 United States VS China: Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share Comparison (2018 & 2022 & 2029)
- 4.2 United States Based Companies VS China Based Companies: Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value Comparison
  - 4.2.1 United States VS China: Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value Comparison (2018 & 2022 & 2029)
  - 4.2.2 United States VS China: Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value Market Share Comparison (2018 & 2022 & 2029)
- 4.3 United States Based Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Companies and Market Share, 2018-2023
  - 4.3.1 United States Based Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Companies, Headquarters (States, Country)
  - 4.3.2 United States Based Companies Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, (2018-2023)
- 4.4 China Based Companies Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue and Market Share, 2018-2023
  - 4.4.1 China Based Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Companies, Company Headquarters (Province, Country)
  - 4.4.2 China Based Companies Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, (2018-2023)
- 4.5 Rest of World Based Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Companies and Market Share, 2018-2023
  - 4.5.1 Rest of World Based Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Companies, Headquarters (States, Country)
  - 4.5.2 Rest of World Based Companies Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, (2018-2023)

## **5 MARKET ANALYSIS BY TYPE**

5.1 World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Overview by Type: 2018 VS 2022 VS 2029

5.2 Segment Introduction by Type

5.2.1 Direct Inhibitors

5.2.2 Signal transduction inhibitors

5.3 Market Segment by Type

5.3.1 World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2018-2023)

5.3.2 World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2024-2029)

5.3.3 World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2018-2029)

## **6 MARKET ANALYSIS BY APPLICATION**

6.1 World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Overview by Application: 2018 VS 2022 VS 2029

6.2 Segment Introduction by Application

6.2.1 Retail Pharmacy

6.2.2 Hospital Pharmacy

6.2.3 Online Pharmacy

6.3 Market Segment by Application

6.3.1 World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2018-2023)

6.3.2 World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2024-2029)

6.3.3 World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2018-2029)

## **7 COMPANY PROFILES**

7.1 Amgen

7.1.1 Amgen Details

7.1.2 Amgen Major Business

7.1.3 Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services



- 7.1.4 Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
- 7.1.5 Amgen Recent Developments/Updates
- 7.1.6 Amgen Competitive Strengths & Weaknesses
- 7.2 Mirati Therapeutics
  - 7.2.1 Mirati Therapeutics Details
  - 7.2.2 Mirati Therapeutics Major Business
  - 7.2.3 Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
  - 7.2.4 Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
  - 7.2.5 Mirati Therapeutics Recent Developments/Updates
  - 7.2.6 Mirati Therapeutics Competitive Strengths & Weaknesses
- 7.3 Novartis
  - 7.3.1 Novartis Details
  - 7.3.2 Novartis Major Business
  - 7.3.3 Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
  - 7.3.4 Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
  - 7.3.5 Novartis Recent Developments/Updates
  - 7.3.6 Novartis Competitive Strengths & Weaknesses
- 7.4 Genentech
  - 7.4.1 Genentech Details
  - 7.4.2 Genentech Major Business
  - 7.4.3 Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
  - 7.4.4 Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
  - 7.4.5 Genentech Recent Developments/Updates
  - 7.4.6 Genentech Competitive Strengths & Weaknesses
- 7.5 Verastem Oncology
  - 7.5.1 Verastem Oncology Details
  - 7.5.2 Verastem Oncology Major Business
  - 7.5.3 Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
  - 7.5.4 Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
  - 7.5.5 Verastem Oncology Recent Developments/Updates

- 7.5.6 Verastem Oncology Competitive Strengths & Weaknesses
- 7.6 Revolution Medicines
  - 7.6.1 Revolution Medicines Details
  - 7.6.2 Revolution Medicines Major Business
  - 7.6.3 Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
  - 7.6.4 Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
  - 7.6.5 Revolution Medicines Recent Developments/Updates
  - 7.6.6 Revolution Medicines Competitive Strengths & Weaknesses
- 7.7 Cardiff Oncology
  - 7.7.1 Cardiff Oncology Details
  - 7.7.2 Cardiff Oncology Major Business
  - 7.7.3 Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
  - 7.7.4 Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
  - 7.7.5 Cardiff Oncology Recent Developments/Updates
  - 7.7.6 Cardiff Oncology Competitive Strengths & Weaknesses
- 7.8 Immuneering Corporation
  - 7.8.1 Immuneering Corporation Details
  - 7.8.2 Immuneering Corporation Major Business
  - 7.8.3 Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
  - 7.8.4 Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
  - 7.8.5 Immuneering Corporation Recent Developments/Updates
  - 7.8.6 Immuneering Corporation Competitive Strengths & Weaknesses
- 7.9 Jacobio Pharmaceuticals
  - 7.9.1 Jacobio Pharmaceuticals Details
  - 7.9.2 Jacobio Pharmaceuticals Major Business
  - 7.9.3 Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
  - 7.9.4 Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
  - 7.9.5 Jacobio Pharmaceuticals Recent Developments/Updates
  - 7.9.6 Jacobio Pharmaceuticals Competitive Strengths & Weaknesses
- 7.10 BridgeBio Pharma
  - 7.10.1 BridgeBio Pharma Details

- 7.10.2 BridgeBio Pharma Major Business
- 7.10.3 BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
- 7.10.4 BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
- 7.10.5 BridgeBio Pharma Recent Developments/Updates
- 7.10.6 BridgeBio Pharma Competitive Strengths & Weaknesses
- 7.11 Deciphera Pharmaceuticals
  - 7.11.1 Deciphera Pharmaceuticals Details
  - 7.11.2 Deciphera Pharmaceuticals Major Business
  - 7.11.3 Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
  - 7.11.4 Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
  - 7.11.5 Deciphera Pharmaceuticals Recent Developments/Updates
  - 7.11.6 Deciphera Pharmaceuticals Competitive Strengths & Weaknesses
- 7.12 Elicio Therapeutics
  - 7.12.1 Elicio Therapeutics Details
  - 7.12.2 Elicio Therapeutics Major Business
  - 7.12.3 Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
  - 7.12.4 Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
  - 7.12.5 Elicio Therapeutics Recent Developments/Updates
  - 7.12.6 Elicio Therapeutics Competitive Strengths & Weaknesses
- 7.13 InventisBio
  - 7.13.1 InventisBio Details
  - 7.13.2 InventisBio Major Business
  - 7.13.3 InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
  - 7.13.4 InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
  - 7.13.5 InventisBio Recent Developments/Updates
  - 7.13.6 InventisBio Competitive Strengths & Weaknesses
- 7.14 Gritstone Bio
  - 7.14.1 Gritstone Bio Details
  - 7.14.2 Gritstone Bio Major Business
  - 7.14.3 Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services

7.14.4 Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023)

7.14.5 Gritstone Bio Recent Developments/Updates

7.14.6 Gritstone Bio Competitive Strengths & Weaknesses

7.15 D3 Bio

7.15.1 D3 Bio Details

7.15.2 D3 Bio Major Business

7.15.3 D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services

7.15.4 D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023)

7.15.5 D3 Bio Recent Developments/Updates

7.15.6 D3 Bio Competitive Strengths & Weaknesses

## **8 INDUSTRY CHAIN ANALYSIS**

8.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Industry Chain

8.2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Upstream Analysis

8.3 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Midstream Analysis

8.4 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Downstream Analysis

## **9 RESEARCH FINDINGS AND CONCLUSION**

## **10 APPENDIX**

10.1 Methodology

10.2 Research Process and Data Source

10.3 Disclaimer

## List Of Tables

### LIST OF TABLES

- Table 1. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
- Table 2. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
- Table 3. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
- Table 4. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Region (2018-2023), (by Headquarter Location)
- Table 5. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Region (2024-2029), (by Headquarter Location)
- Table 6. Major Market Trends
- Table 7. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
- Table 8. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value by Region (2018-2023) & (USD Million)
- Table 9. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value Forecast by Region (2024-2029) & (USD Million)
- Table 10. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue by Player (2018-2023) & (USD Million)
- Table 11. Revenue Market Share of Key Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Players in 2022
- Table 12. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Industry Rank of Major Player, Based on Revenue in 2022
- Table 13. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Company Evaluation Quadrant
- Table 14. Head Office of Key Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Player
- Table 15. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Company Product Type Footprint
- Table 16. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Company Product Application Footprint
- Table 17. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Mergers & Acquisitions Activity
- Table 18. United States VS China Kirsten Rat Sarcoma Viral Oncogene Homolog

(KRAS) Inhibitors Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)  
Table 19. United States VS China Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 20. United States Based Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Companies, Headquarters (States, Country)

Table 21. United States Based Companies Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, (2018-2023) & (USD Million)

Table 22. United States Based Companies Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share (2018-2023)

Table 23. China Based Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Companies, Headquarters (Province, Country)

Table 24. China Based Companies Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, (2018-2023) & (USD Million)

Table 25. China Based Companies Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share (2018-2023)

Table 26. Rest of World Based Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Companies, Headquarters (States, Country)

Table 27. Rest of World Based Companies Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, (2018-2023) & (USD Million)

Table 28. Rest of World Based Companies Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share (2018-2023)

Table 29. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type, (USD Million), 2018 & 2022 & 2029

Table 30. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2018-2023) & (USD Million)

Table 31. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2024-2029) & (USD Million)

Table 32. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application, (USD Million), 2018 & 2022 & 2029

Table 33. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2018-2023) & (USD Million)

Table 34. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2024-2029) & (USD Million)

Table 35. Amgen Basic Information, Area Served and Competitors

Table 36. Amgen Major Business

Table 37. Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services

Table 38. Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors

Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 39. Amgen Recent Developments/Updates

Table 40. Amgen Competitive Strengths & Weaknesses

Table 41. Mirati Therapeutics Basic Information, Area Served and Competitors

Table 42. Mirati Therapeutics Major Business

Table 43. Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services

Table 44. Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 45. Mirati Therapeutics Recent Developments/Updates

Table 46. Mirati Therapeutics Competitive Strengths & Weaknesses

Table 47. Novartis Basic Information, Area Served and Competitors

Table 48. Novartis Major Business

Table 49. Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services

Table 50. Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 51. Novartis Recent Developments/Updates

Table 52. Novartis Competitive Strengths & Weaknesses

Table 53. Genentech Basic Information, Area Served and Competitors

Table 54. Genentech Major Business

Table 55. Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services

Table 56. Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 57. Genentech Recent Developments/Updates

Table 58. Genentech Competitive Strengths & Weaknesses

Table 59. Verastem Oncology Basic Information, Area Served and Competitors

Table 60. Verastem Oncology Major Business

Table 61. Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services

Table 62. Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 63. Verastem Oncology Recent Developments/Updates

Table 64. Verastem Oncology Competitive Strengths & Weaknesses

Table 65. Revolution Medicines Basic Information, Area Served and Competitors

Table 66. Revolution Medicines Major Business

Table 67. Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services

- Table 68. Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 69. Revolution Medicines Recent Developments/Updates
- Table 70. Revolution Medicines Competitive Strengths & Weaknesses
- Table 71. Cardiff Oncology Basic Information, Area Served and Competitors
- Table 72. Cardiff Oncology Major Business
- Table 73. Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
- Table 74. Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 75. Cardiff Oncology Recent Developments/Updates
- Table 76. Cardiff Oncology Competitive Strengths & Weaknesses
- Table 77. Immuneering Corporation Basic Information, Area Served and Competitors
- Table 78. Immuneering Corporation Major Business
- Table 79. Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
- Table 80. Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 81. Immuneering Corporation Recent Developments/Updates
- Table 82. Immuneering Corporation Competitive Strengths & Weaknesses
- Table 83. Jacobio Pharmaceuticals Basic Information, Area Served and Competitors
- Table 84. Jacobio Pharmaceuticals Major Business
- Table 85. Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
- Table 86. Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 87. Jacobio Pharmaceuticals Recent Developments/Updates
- Table 88. Jacobio Pharmaceuticals Competitive Strengths & Weaknesses
- Table 89. BridgeBio Pharma Basic Information, Area Served and Competitors
- Table 90. BridgeBio Pharma Major Business
- Table 91. BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
- Table 92. BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 93. BridgeBio Pharma Recent Developments/Updates
- Table 94. BridgeBio Pharma Competitive Strengths & Weaknesses
- Table 95. Deciphera Pharmaceuticals Basic Information, Area Served and Competitors



- Table 96. Deciphera Pharmaceuticals Major Business
- Table 97. Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
- Table 98. Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 99. Deciphera Pharmaceuticals Recent Developments/Updates
- Table 100. Deciphera Pharmaceuticals Competitive Strengths & Weaknesses
- Table 101. Elicio Therapeutics Basic Information, Area Served and Competitors
- Table 102. Elicio Therapeutics Major Business
- Table 103. Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
- Table 104. Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 105. Elicio Therapeutics Recent Developments/Updates
- Table 106. Elicio Therapeutics Competitive Strengths & Weaknesses
- Table 107. InventisBio Basic Information, Area Served and Competitors
- Table 108. InventisBio Major Business
- Table 109. InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
- Table 110. InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 111. InventisBio Recent Developments/Updates
- Table 112. InventisBio Competitive Strengths & Weaknesses
- Table 113. Gritstone Bio Basic Information, Area Served and Competitors
- Table 114. Gritstone Bio Major Business
- Table 115. Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
- Table 116. Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 117. Gritstone Bio Recent Developments/Updates
- Table 118. D3 Bio Basic Information, Area Served and Competitors
- Table 119. D3 Bio Major Business
- Table 120. D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product and Services
- Table 121. D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 122. Global Key Players of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Upstream (Raw Materials)

Table 123. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Typical Customers

## List Of Figures

### LIST OF FIGURES

Figure 1. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Picture

Figure 2. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Total Market Size: 2018 & 2022 & 2029, (USD Million)

Figure 3. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Total Market Size (2018-2029) & (USD Million)

Figure 4. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)

Figure 5. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Region (2018-2029), (by Headquarter Location)

Figure 6. United States Based Company Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (2018-2029) & (USD Million)

Figure 7. China Based Company Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (2018-2029) & (USD Million)

Figure 8. Europe Based Company Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (2018-2029) & (USD Million)

Figure 9. Japan Based Company Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (2018-2029) & (USD Million)

Figure 10. South Korea Based Company Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (2018-2029) & (USD Million)

Figure 11. ASEAN Based Company Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (2018-2029) & (USD Million)

Figure 12. India Based Company Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (2018-2029) & (USD Million)

Figure 13. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value (2018-2029) & (USD Million)

Figure 16. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value Market Share by Region (2018-2029)

Figure 17. United States Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value (2018-2029) & (USD Million)

Figure 18. China Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value (2018-2029) & (USD Million)

Figure 20. Japan Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value (2018-2029) & (USD Million)

Figure 23. India Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Markets in 2022

Figure 27. United States VS China: Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type in 2022

Figure 31. Direct Inhibitors

Figure 32. Signal transduction inhibitors

Figure 33. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2018-2029)

Figure 34. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 35. World Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application in 2022

Figure 36. Retail Pharmacy

Figure 37. Hospital Pharmacy

Figure 38. Online Pharmacy

Figure 39. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Industrial Chain

Figure 40. Methodology

Figure 41. Research Process and Data Source

## I would like to order

Product name: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/GDBB6AF65585EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GDBB6AF65585EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

